Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 88150-42-9 Chemical Structure| 88150-42-9

Structure of Amlodipine
CAS No.: 88150-42-9

Chemical Structure| 88150-42-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Amlodipine is a long-acting calcium channel blocker used to lower blood pressure and prevent chest pain.

Synonyms: Intervask; UK-48340; Pelmec

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Amlodipine

CAS No. :88150-42-9
Formula : C20H25ClN2O5
M.W : 408.88
SMILES Code : O=C(C1=C(COCCN)NC(C)=C(C(OC)=O)C1C2=CC=CC=C2Cl)OCC
Synonyms :
Intervask; UK-48340; Pelmec
MDL No. :MFCD00864687
InChI Key :HTIQEAQVCYTUBX-UHFFFAOYSA-N
Pubchem ID :2162

Safety of Amlodipine

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H318-H373-H410
Precautionary Statements:P264-P270-P280-P305+P351+P338-P310-P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
Ishikawa cells 10 μM, 15 μM 12 h To evaluate the effect of AM on the apoptosis of Ishikawa cells, the results showed that AM induced cell apoptosis. PMC9563405
Ishikawa cells 15 μM 48 h To evaluate the effect of AM on the proliferation of Ishikawa cells, the results showed that AM inhibited cell proliferation. PMC9563405
Ishikawa cells 0, 1.25, 5, 10, 12.5, 20, 25, 40, 50 μM 72 h To evaluate the effect of AM on the proliferation of Ishikawa cells, the results showed that AM inhibited cell proliferation. PMC9563405
MGC803 cells 0, 5, 10, 20 µM 24, 48, 72 h To evaluate the effect of amlodipine on cell proliferation, results showed that amlodipine inhibited GC cell proliferation in a dose-dependent manner. PMC11024009
HGC27 cells 0, 5, 10, 20 µM 24, 48, 72 h To evaluate the effect of amlodipine on cell proliferation, results showed that amlodipine inhibited GC cell proliferation in a dose-dependent manner. PMC11024009
Vascular smooth muscle cells (VSMCs) 5 μM 24 h To investigate the effect of amlodipine on VSMC differentiation, results showed that amlodipine increased the expression of α-SMA, CNN1, and SM-MHC but decreased OPN expression. PMC6555864

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Subcutaneous transplanted tumor model Peritoneal injection 15 mg/kg, 20 mg/kg Every two days for 14 days To evaluate the inhibitory effect of AM on tumor growth in vivo, the results showed that AM significantly inhibited tumor growth. PMC9563405
NKG mice Subcutaneous xenograft model Oral 10 mg/kg Once daily for 28 days To evaluate the effect of amlodipine on tumor growth in vivo, results showed that amlodipine significantly reduced tumor volume and weight in the SYT4-OE group. PMC11024009
Spontaneously hypertensive rats (SHRs) Spontaneously hypertensive rat model Oral 2 mg/kg Once daily for 10 weeks To investigate the effect of amlodipine on blood pressure and vascular function in SHRs, results showed that amlodipine promoted VSMC differentiation by upregulating miR-21 expression. PMC6555864
Sprague-Dawley rats Amlodipine-induced shock model Intravenous injection 17 mg/kg Three doses at 5, 30, and 60 minutes To evaluate the efficacy of methylene blue in an amlodipine-induced shock model. Results showed that the methylene blue group had significantly higher survival time, heart rate, and mean arterial pressure compared to the control group. PMC4565597
Rats High-fat diet-induced non-alcoholic fatty liver disease model Intraperitoneal injection 5mg/kg Twice a week for 12 weeks Vitamin D supplementation alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating gut microbiota and metabolism. PMC9932697

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05467384 Hypercholesterolemia|Hypertens... More >>ion|Cholesterol Deposition Less << PHASE4 COMPLETED 2017-06-30 -
NCT02904291 Obesity, Morbid RECRUITING 2025-05-26 St. Olavs University Hospital,... More >> Trondheim, Norway Less <<
NCT01738945 We Searched for the Effects of... More >> Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria. Less << PHASE4 COMPLETED 2025-05-09 Gulhane School of Medicine, An... More >>kara, 06018, Turkey Less <<
NCT04559074 Hypertension PHASE4 COMPLETED 2021-11-19 William Harvey Research Instit... More >>ute Clinical Research Centre, Queen Mary University of London, London, London - City Of London, EC1m 6BQ, United Kingdom|Queen Mary University London, London, EC1M 6BQ, United Kingdom Less <<
NCT01835418 Hypertension UNKNOWN - -
NCT00602017 Hypertension|Chronic Stable An... More >>gina|Vasospastic Angina Less << COMPLETED 2025-05-04 Gateway Medical Research, Inc.... More >>, Saint Charles, Missouri, 63301, United States Less <<
NCT00159692 Hypertension PHASE4 COMPLETED 2025-08-05 -
NCT01125254 Thalassemia Major PHASE2|PHASE3 COMPLETED 2025-07-11 University of Campinas, Campin... More >>as, SP, 13100, Brazil Less <<
NCT00443456 Hypertension PHASE3 COMPLETED 2025-06-08 Pfizer Investigational Site, C... More >>hikushino, Fukuoka, Japan|Pfizer Investigational Site, Kitakyushu, Fukuoka, Japan|Pfizer Investigational Site, Yokohama, Kanagawa, Japan|Pfizer Investigational Site, Iruma, Saitama, Japan|Pfizer Investigational Site, Koshigaya, Saitama, Japan|Pfizer Investigational Site, Edogawa-ku, Tokyo, Japan|Pfizer Investigational Site, Setagaya-ku, Tokyo, Japan|Pfizer Investigational Site, Sumida-ku, Tokyo, Japan|Pfizer Investigational Site, Fukuoka, Japan Less <<
NCT06713785 Hypertension PHASE4 WITHDRAWN 2021-05-31 -
NCT01252563 Hypertension COMPLETED 2025-10-12 -
NCT00151619 Chronic Heart Failure PHASE2 TERMINATED - Service de Réanimation Médical... More >>e - H?pital Raymond Poincaré, Garches, 92380, France|Service de Réadaptation Cardio-Vasculaire - Clinique St Yves, Rennes, 35044, France Less <<
NCT04179019 Primary Aldosteronism|Primary ... More >>Aldosteronism Due to Adrenal Hyperplasia (Bilateral) Less << PHASE2 COMPLETED 2023-12-30 Anand Vaidya, Boston, Massachu... More >>setts, 02115, United States Less <<
NCT00601302 Hypertension|Chronic Stable An... More >>gina|Vasospastic Angina Less << COMPLETED 2025-05-04 Gateway Medical Research, Inc.... More >>, Saint Charles, Missouri, 63301, United States Less <<
NCT01395199 Thalassemia|Iron Overload PHASE3 COMPLETED 2025-02-15 Universidade Estadual de Campi... More >>nas, Campinas, SP, 13100000, Brazil Less <<
NCT01131923 Healthy PHASE1 COMPLETED 2025-12-02 AAI Clinic, Chapel Hill, North... More >> Carolina, 27514, United States Less <<
NCT01131936 Healthy PHASE1 COMPLETED 2025-11-02 AAI Clinic, Chapel Hill, North... More >> Carolina, 27514, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.45mL

0.49mL

0.24mL

12.23mL

2.45mL

1.22mL

24.46mL

4.89mL

2.45mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories